Holen Sie sich die Stockscreener-App
2.7892
10.47%
0.2792
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
FY2025 Earnings Estimate for RCKT Issued By Chardan Capital - Defense World
Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World
Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World
Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World
Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Tar - GuruFocus
RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus
Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com
Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider
Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to “Hold” at Leerink Partnrs - Defense World
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded to “Sell” Rating by The Goldman Sachs Group - Defense World
RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN
William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN
JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com
Rocket Pharmaceuticals’ (RCKT) Neutral Rating Reaffirmed at JPMorgan Chase & Co. - Defense World
Rocket Pharmaceuticals’ (RCKT) “Sell” Rating Reaffirmed at The Goldman Sachs Group - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives “Hold” Rating from Jefferies Financial Group - Defense World
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga
Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus
Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha
Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN
Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade - GuruFocus
Rocket Pharmaceuticals (RCKT) Sees Significant Analyst Downgrade | RCKT Stock News - GuruFocus
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Deutsche Bank AG - Defense World
RCKT Stock Tanks on Patient Death in Danon Disease Study - Yahoo Finance
Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amid Clinical Hold | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Receives Downgrade and Price Targe - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Downgrade Amid Clinical Tria - GuruFocus
Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Ca - GuruFocus
Rocket Pharmaceuticals (RCKT) Target Price Revised by Chardan Capital | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Challenges After Clinical Hold | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Price Target Cut Amidst Clin - GuruFocus
Scotiabank cuts Rocket Pharmaceuticals target to $19 - Investing.com
Chardan Cuts Price Target on Rocket Pharmaceuticals to $17 From $46, Keeps Buy Rating - marketscreener.com
This Informatica Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Jefferies Downgrades Rocket Pharmaceuticals (RCKT) Rating and Pr - GuruFocus
Rocket Pharmaceuticals (RCKT) Faces Setback Amid Clinical Trial Death | RCKT Stock News - GuruFocus
Needham Downgrades Rocket Pharmaceuticals to Hold From Buy - marketscreener.com
Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA H - GuruFocus
Rocket Pharmaceuticals (RCKT) Downgraded by Jefferies Amid FDA Hold | RCKT Stock News - GuruFocus
Morgan Stanley cuts Rocket Pharmaceuticals stock rating, slashes PT - Investing.com
Jefferies cuts Rocket Pharmaceuticals stock rating, slashes target - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Hold Rating from Needham & Company LLC - Defense World
Patient Death In Rocket Pharma Trial Triggers Downgrades, But Retail Traders Bet Big On Strong Recovery - Investing.com India
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Leerink cuts Rocket Pharmaceuticals stock rating, slashes PT to $8 By Investing.com - Investing.com Canada
Death in Rocket Pharma Gene Therapy Study Puts Spotlight on Trial Change Intended to Improve Safety - MedCity News
1.76%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):